Cartesian Therapeutics, Inc.
RNAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.02 | -0.01 | 0.12 |
| FCF Yield | -6.36% | -7.45% | -7.08% | -1.66% |
| EV / EBITDA | -3.82 | 7.46 | -8.44 | -27.99 |
| Quality | ||||
| ROIC | -5.81% | -5.73% | -5.50% | -6.44% |
| Gross Margin | -2,731.19% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.43 | -1.10 | 1.30 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -68.39% | -72.38% | -25.52% | -29.44% |
| Free Cash Flow Growth | 16.03% | 16.82% | -213.78% | -202.87% |
| Safety | ||||
| Net Debt / EBITDA | 3.71 | -8.92 | 8.02 | 20.95 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 128.11 | 106.91 | 144.41 | -103.40 |